MRK

Should I Buy Pfizer? 3 Pros, 3 Cons

Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More

10 Defensive Stocks Taking on Some Froth

Defensive stocks have been on fire and outpacing the broader market for months. However, while many still offer enticing yields, you'll be overpaying by jumping in now. More

3 Pharma Stocks to Buy Into Earnings

We'll learn a lot about healthcare names over the course of this earnings season -- I'm expecting big things from these three drugmakers. More

Merck, Pfizer to Team Up on New Diabetes Drug

Merck will partner with Pfizer to develop new diabetes treatments around Pfizer's experimental ertugliflozin drug. More

6 Call Contenders Releasing Earnings

These bullish stocks are all reporting this week -- why not take advantage with call options? More

Amgen May Have Hit With Migraine Drugs

Researchers at biotechnology firm Amgen are studying how skin reacts to chili pepper oil to help develop new drugs for migranes. More

Amgen Settles Kickbacks Lawsuit for $25M

Under a settlement with the U.S. Department of Justice, Amgen will pay $24.9 million to settle claims it paid kickbacks to care providers to promote a drug. More